Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with stalin + fibrate combination;Vliv vícenenasycených mastných kyselin řady n-3 na plazmatické lipidy, lipoperoxidaci LDL, homocystein a ukazatele zánětu u diabetické dyslipidémie, léčené kombinací statin + fibrát

Casopis Lekaru Ceskych

Volumn 144, Issue 11, 2005, Pages 737-741

  Zeman, Miroslav ^a,b   Zak A ^a   Vecka, M ^a   Tvrzicka E ^a   Pisarikova A ^a   Stankova B ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NONE   (Czech Republic)

Author keywords

Diabetic dyslipidemia; Fatty acids; Homocysteine; Lipoperoxidation; n 3 PUFA

Indexed keywords

CHOLESTEROL; FATTY ACID; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPID; PHOSPHATIDYLCHOLINE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; HOMEOSTASIS; HUMAN; LIPID BLOOD LEVEL; LIPID PEROXIDATION; SUPPLEMENTATION;

ADULT; ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FEMALE; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INFLAMMATION MEDIATORS; LIPID PEROXIDATION; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PRAVASTATIN; PROCETOFEN; SINGLE-BLIND METHOD;

EID: 28344446005     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Xydakis, A. M., Ballantyne, C. M.: Combination therapy for combined dyslipidemia. Am. J. Cardiol., 2002, 90 (Suppl.), s. 21K-29K.
2. Athyros, V. G., Papageorgiou, A. A., Athyrou, V. V. et al.: Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care, 2002, 25, s. 1198-1202.
3. American Diabetes Association: Management of dyslipidemia in adults with diabetes [Position Statement]. Diabetes Care, 2002, 25, s. 74-77.
4. Kanters, S. D. J. M., Algra, A., DeBruin, T. W. A. et al.: Intensive lipid-lowering strategy in patients with diabetes mellitus. Diabet. Med., 1999, 16, s. 500-508.
5. Harris, W. S.: Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J. Lipid. Res., 1989, 30, s. 785-807.
6. Knopp, R. H.: Drug treatment of lipid disorders. N. Engl. J. Med., 1999, 341, s. 498-511.
7. Erkkilä, A. T., Lehto, S., Pyörälä, K., Uusitupa, M. I. J.: n-3 fatty acids and 5-y risk of death and cardiovascular disease events in patients with coronary artery disease. Am. J. Clin. Nutr., 2003, 78, s. 65-71.
8. Bucher, H. C., Hengstler, P., Schindler, C., Meier, G.: n-3 Polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am. J. Med., 2002, 112, s. 298-304.
9. Connor, W. E.: Importance of n-3 fatty acids in health and disease. Am. J. Clin. Nutr., 2000, 71 (Suppl.), s. 171S-175S.
10. Goodfellow, J., Bellamy, M. F., Ramsey, M. W. et al.: Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J. Am. Coll. Cardiol., 2000, 35, s. 265-270.
11. Kasim, S. E.: Dietary marine fish oils and insulin action in type 2 diabetes. Ann. NY Acad. Sci., 1993, 683, s. 250-257.
12. Nenseter, M. S., Drevon, C. A.: Dietary polyunsaturates and peroxidation of low density lipoprotein. Curr. Opin. Lipidol., 1996, 7, s. 8-13.
13. Evans, J. L., Goldfine, I. D., Maddux, B. A., Grodsky, G. M.: Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes, 2003, 52, s. 1-8.
14. Olszewski, A. J., McCully, K. S.: Fish oil decreases serum homocysteine in hyperlipemic men. Coron. Artery Dis., 1993, 4, s. 53-60.
15. Clarke, R., Daly, L., Robinson, K et al.: Hyperhomocysteinemia: An independent risk factor for vascular disease. N. Engl. J. Med., 1991, 324, s. 1149-1155.
16. Bolander-Gouaille, C.: Focus on homocysteine and the vitamins involved in its metabolism. 2nd edition. Springer, France, 2002,s. 32-69.
17. Soinio, M., Marniemi, J., Laakso, M. et al.: Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann. Intern. Med., 2004, 140, s. 94-100.
18. American Diabetes Association: Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care, 2001, 24 (Suppl.), s. S44-S47.
19. Ahotupa, M., Ruutu, M., Mantyla, E.: Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin. Biochem., 1996, 29, s. 139-144.
20. Tvrzická, E., Vecka, M., Staňková, B., Žák, A.: Analysis of fatty acids in plasma lipoproteins by gas chromatography-flame ionisation detection. Quantitative aspects. Anal. Chim. Acta, 2002, 465, s. 337-350.
21. Araki, A., Sako, Y.: Determination of free and total homocysteine in human plasma by HPLC with fluorescence detection. J. Chromatogr., 1987, 422, s. 43-52.
22. Contacos, C., Barter, P. J., Sullivan, D. R.: Effect of pravastatin and omega.-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arteriocler. Thromb., 1995, 13, s. 1755-1762.
23. Nordoy, A., Bonaa, K. H., Nilsen, H. AT al.: Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J. Intern. Med., 1998, 243, s. 163-170.
24. Nordoy, A., Hansen, J. B., Brox, J., Svensson, B.: Effects of atorvastatin and Ω-3 fatty acids on LDL subfractions and postprandial hyperlipidemia in patients with combined hyperlipemia. Nutr. Metab. Cardiovasc. Dis., 2001, 11, s. 7-16.
25. Durrington, P. N., Bhatnagar, D., Mackness, M. I. et al.: An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridemia. Heart, 2001, 85, s. 544-548.
26. Žák, A., Hrabák, P., Zeman, M.: Treatment of severe hypertriglyceridemia with a combination of n-3 fatty acids and bezafibrate. In: Treatment of severe dyslipidemia in the prevention of coronary heart disease, 3rd Int. Symp., Munich, 1990 (Gotto, A. M. Jr., Mancini, M., Richter, W. O., Schwandt, P. eds.), Basel Karger, 1992, s. 240-244.
27. Stalenhoef, A. F. H., De Graaf, J., Wittekoek, M. E. et al.: The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis, 2000, 153, s. 129-138.
28. Kesavulu, M. M., Kameswararao, B., Apparao, Ch. et al.: Effects of omega-3 fatty acids on lipid peroxidation and antioxidant enzyme status in type 2 diabetic patients. Diabetes Metab., 2002, 28, s. 20-26.
29. Montori, V. M., Farmer, A., Wollan, P. C., Dineen S. F.: Fish oil supplementation in type 2 diabetes. Diabetes Care. 2000, 23, s. 1407 az 1415.
30. Abe, Y., El-Masru, B., Kimball, K. T. et al.: Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler. Thromb. Vase. Biol., 1998, 18, s. 723-731.
31. Chen, H., Li, D., Roberts, G. J. AT al.: EPA and DHA attenuate ox-LDL-induced expression of adhesion molecules in human coronary artery endothelial cells via protein kinase B pathway. J. Mol. Cell Cardiol., 2003, 35, s. 769-775.
32. Yli-Jama, P., Seljeflot, I., Meyer, H. E. et al.: Serum non-esterified very long-chain PUFA are associated with markers of endothelial dysfunction. Atherosclerosis, 2002, 164, s. 275-281.
33. Buysschaert, M., Dramais, A.-S., Walleraacq, P. E., Hermans, M. P.: Hyperhomocysteinemia in type 2 diabetes. Relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care, 2000, 23, s. 1816-1822.
34. Grundt, H., Nilsen, D. W. T., Hetland, Ø. et al.: Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia. Thromb. Haemost., 1999, 81, s. 561-565.
35. Grundt, H., Nilsen, D. W. T., Mansoor, M. A. et al.: Reduction in homocysteine by a-3 polyunsaturated fatty acids after 1 year in a randomised double-blind study following an acute myocardial infarction: no effect on endothelial adhesion properties. Pathophysiol. Haemost. Thromb., 2003, 33, s. 88-95.
36. Piolot, A., Blache, D., Boulet, L. et al.: Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health. J. Lab. Clin. Med., 2003, 141, s. 41-49.
37. Bisonnette, R. et al.: Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis, 2001, 155, s. 455-462.
38. Carlsen, S., Folling, I., Grill, V. et al.: Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand. J. Clin. Lab. Invest., 1997, 57, s. 521-527.